REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Rating of “Moderate Buy” from Analysts

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have received an average rating of “Moderate Buy” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $32.78.

A number of research firms recently commented on RGNX. Chardan Capital reiterated a “buy” rating and issued a $52.00 price target on shares of REGENXBIO in a research note on Thursday, March 20th. Raymond James began coverage on REGENXBIO in a research report on Friday, February 7th. They issued an “outperform” rating and a $27.00 target price for the company. Leerink Partners set a $24.00 price target on REGENXBIO in a research report on Tuesday, March 18th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of REGENXBIO in a report on Tuesday, January 21st. Finally, Morgan Stanley boosted their target price on shares of REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, March 14th.

REGENXBIO Trading Down 0.1 %

REGENXBIO stock opened at $8.20 on Friday. REGENXBIO has a 52 week low of $5.62 and a 52 week high of $22.42. The stock has a market cap of $410.71 million, a P/E ratio of -1.63 and a beta of 1.35. The stock has a 50 day moving average of $7.37 and a 200-day moving average of $8.82.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.26. The firm had revenue of $21.21 million for the quarter, compared to the consensus estimate of $23.70 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. As a group, equities analysts predict that REGENXBIO will post -4.84 earnings per share for the current fiscal year.

Institutional Investors Weigh In On REGENXBIO

Several hedge funds have recently modified their holdings of RGNX. GAMMA Investing LLC lifted its position in shares of REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 2,510 shares in the last quarter. FMR LLC raised its stake in REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of REGENXBIO in the fourth quarter valued at $54,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of REGENXBIO in the fourth quarter worth $79,000. Finally, Laurion Capital Management LP purchased a new position in shares of REGENXBIO during the fourth quarter valued at $79,000. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.